

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0275584 A1 Adusumilli

(43) **Pub. Date:**

Sep. 9, 2021

(54) IMMUNE CELL COMPOSITIONS AND METHODS OF USE FOR TREATING VIRAL AND OTHER INFECTIONS

(71) Applicant: Memorial Sloan Kettering Cancer

Center, New York, NY (US)

(72) Inventor: Prasad S. Adusumilli, New York, NY

Assignee: Memorial Sloan Kettering Cancer

Center, New York, NY (US)

(21) Appl. No.: 16/329,142

(22) PCT Filed: Aug. 29, 2017

(86) PCT No.: PCT/US2017/049085

§ 371 (c)(1),

Feb. 27, 2019 (2) Date:

Related U.S. Application Data

(60) Provisional application No. 62/381,219, filed on Aug. 30, 2016, provisional application No. 62/468,881, filed on Mar. 8, 2017.

Publication Classification

(51) Int. Cl.

A61K 35/17 (2006.01)(2006.01)C07K 14/705

C07K 14/71 (2006.01)(2006.01)C12N 9/22

(52) U.S. Cl.

CPC A61K 35/17 (2013.01); C07K 14/70521 (2013.01); C07K 14/71 (2013.01); C07K 2319/70 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 9/22 (2013.01)

(57)ABSTRACT

Disclosed herein are cells that are immune cells, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, and optionally recombinantly express a chimeric antigen receptor (CAR), wherein the CAR binds to a viral antigen. In certain embodiments, the immune cell is an immunostimulatory cell, such as a T cell. In certain embodiments, the immune cell is an immunoinhibitory cell, such as a regulatory T cell. Also disclosed herein are immune cells that recognize and are sensitized to a viral antigen, which immune cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell. The cells can be sensitized to an antigen that is a viral antigen. Additionally provided are methods of using such cells to treat a viral infection in a subject in need thereof.

Specification includes a Sequence Listing.

